News

Ablynx targets allergic asthma
Enlarge image

BusinessBelgiumAustriaSwitzerland

Ablynx targets allergic asthma

08.05.2013 - Belgian single chain camelidae antibody producer Ablynx has started development of an anti-IgE nanobody, code-named ALV-0962.

The Ghent-based company announced the compound will enter clinical development after Q2/2014. Ablynx believes its treatment of severe allergic asthma can outcompete Roche’s /Novartis’ marketed allergic asthma antibody Xolair (omalizumab) due to its "unique" dual mode of action. The company suggested the preclinical compound could displace receptor-bound IgE as well as binding free IgE molecules. 

Due to its mode of action, Ablynx believes that ALX-0962 could address a wider patient population, including those currently not eligible to be treated with omalizumab (Xolair®).  Currently, many allergic asthma treatments are in clinical development including Phase II compounds from Swedish Resistentia Pharmaceuticals AB, Takeda, Actelion or Cytos Biotechnology (CYT003-QbG10).

IgE is a key mediator in initiating an allergic reaction upon allergen exposure. IgE is a clinically and commercially validated mechanism to treat allergic asthma. Omalizumab currently is the only anti-IgE biologic approved for the treatment of patients with moderate to severe persistent allergic asthma, inadequately controlled with inhaled corticosteroids. Xolair® generated sales of $1.26bn in 2012.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/ablynx-enters-allergic-asthma-arena.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.28 CHF7.54%
  • FORMYCON29.50 EUR3.91%
  • EPIGENOMICS5.72 EUR3.06%

FLOP

  • CYTOS0.64 CHF-3.03%
  • VITA 345.65 EUR-2.59%
  • BAYER133.40 EUR-2.56%

TOP

  • SYNGENTA423.60 CHF29.8%
  • EVOLVA1.82 CHF19.0%
  • BASILEA131.30 CHF16.1%

FLOP

  • CYTOS0.64 CHF-34.7%
  • MEDIGENE8.55 EUR-18.2%
  • 4SC4.55 EUR-12.5%

TOP

  • WILEX4.07 EUR408.8%
  • FORMYCON29.50 EUR335.1%
  • 4SC4.55 EUR299.1%

FLOP

  • MOLOGEN4.93 EUR-53.7%
  • PAION2.52 EUR-27.4%
  • BIOFRONTERA2.25 EUR-26.9%

No liability assumed, Date: 28.05.2015